Name : Human ICOS/CD278 (Q50A) Protein
Product Source :
Recombinant Human ICOS/CD278 (Q50A) Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Glu21-Phe141.[Accession | Q9Y6W8-1]
Molecular Weight :
The protein has a predicted MW of 40.45 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human ICOS (Q50A) on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human ICOS (Q50A) is greater than 95% as determined by SEC-HPLC. SPR Data Human ICOS, hFc Tag (Q50A) captured on CM5 Chip via Protein A can bind Human B7-H2, His Tag with an affinity constant of 41.98 nM as determined in SPR assay (Biacore T200).
Background :
Inducible co-stimulator (ICOS), also called AILIM (activiation-inducible lymphocyte immunomediatory molecule) and CRP-1 (CD28-related protein-1), is a member of the growing CD28 family of immune costimulatory receptors. Other family members are CD28, CTLA-4 and PD-1. Human ICOS is a homodimeric type I transmembrane protein consisting of 199 amino acids (aa) with a putative 20 aa signal sequence, a 121 aa extracellular domain, a 23 aa transmembrane region, and a 35 aa cytoplasmic domain.
Synonyms :
AILIM; CD278; CRP-1; CVID1; ICOS; MGC39850
References & Citations :
(1) ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. 2019
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
GSTA1 Protein
MME Protein
Popular categories:
Fc Receptor-like 6 (FCRL6)
Cathepsin